Health
World-first human trial finds arthritis drug can suppress progression of type 1 diabetes
![](https://canadanewsmedia.ca/wp-content/uploads/2023/12/insulin.jpg)
Researchers at St Vincent’s Institute of Medical Research (SVI) in Melbourne have shown that a commonly prescribed rheumatoid arthritis drug can suppress the progression of type 1 diabetes.
The world-first human trial, published in the New England Journal of Medicine and led by SVI’s Professor Thomas Kay, showed that a drug called baricitinib can safely and effectively preserve the body’s own insulin production and suppress the progression of type 1 diabetes in people who initiated treatment within 100 days of diagnosis.
“When type 1 diabetes is first diagnosed there is a substantial number of insulin-producing cells still present. We wanted to see whether we could protect further destruction of these cells by the immune system. We showed that baricitinib is safe and effective at slowing the progression of type 1 diabetes in people who have been recently diagnosed,” said Professor Kay.
This ground-breaking research shows promise as the first disease-modifying treatment of its kind for type 1 diabetes that can be delivered as a tablet.
“It is tremendously exciting for us to be the first group anywhere in the world to test the efficacy of baricitinib as a potential type 1 diabetes treatment,” said Professor Kay.
“Up until now, people with type 1 diabetes have been reliant on insulin delivered via injection or infusion pump. Our trial showed that, if started early enough after diagnosis, and while the participants remained on the medication, their production of insulin was maintained. People with type 1 diabetes in the trial who were given the drug required significantly less insulin for treatment.”
Management of the lifelong autoimmune disease is incredibly burdensome on those diagnosed and their families, requiring meticulous glucose monitoring and insulin administration day and night to stay alive.
Up until insulin’s discovery more than 100 years ago, type 1 diabetes was a fatal condition. Despite insulin’s life-saving role, the therapy itself is potentially dangerous if too much or too little is administered, and the condition still comes with long-term complications, including heart attack and stroke, vision impairment, kidney disease and nerve damage.
“We are very optimistic that this treatment will become clinically available. This would be a huge step-change in how type 1 diabetes is managed and we believe it shows promise as a fundamental improvement in the ability to control type 1 diabetes,” said Professor Helen Thomas, preclinical lead on the trial.
The randomized, double-blind, placebo-controlled human trial of the drug baricitinib monitored the blood glucose and insulin production of 91 participants over the course of one year. Of these, 60 were given baricitinib and 31 were given a placebo. All trial participants were aged between 10 years old and 30 years old and started on the trial within 100 days of having been diagnosed with type 1 diabetes.
Participants continued with their prescribed insulin therapy throughout the duration of the study. Researchers monitored participants’ total daily dose of insulin, the amount of insulin produced endogenously (by their own pancreas), their blood glucose levels, and their HbA1C levels. HbA1c, or glycated hemoglobin, is a measure of average blood glucose (sugar) levels for the last two to three months.
Baricitinib blocks an enzyme that normally helps to transmit signals that regulate the immune system and inflammation. The drug is currently prescribed for the treatment of rheumatoid arthritis, which is another autoimmune disease. It is thought that the drug similarly dampens down the immune response that is mounted against insulin-producing cells in people with newly diagnosed type 1 diabetes, thus delaying the onset of full-blown symptoms of the disease, improving glucose control and reducing potential for detrimental longer term health effects.
More information:
Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes, New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2306691
Citation:
World-first human trial finds arthritis drug can suppress progression of type 1 diabetes (2023, December 6)
retrieved 6 December 2023
from https://medicalxpress.com/news/2023-12-world-first-human-trial-arthritis-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
![728x90x4](https://i.ibb.co/ZTzkrwT/728x90x4.jpg)
Health
FREEDOM_PARTICLE_CONVERTER_MAIN_9456127591_MAIN – Energy Liberation Army
Product Name: FREEDOM_PARTICLE_CONVERTER_MAIN_9456127591_MAIN – Energy Liberation Army
All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.
FREEDOM_PARTICLE_CONVERTER_MAIN_9456127591_MAIN – Energy Liberation Army is backed with a 60 Day No Questions Asked Money Back Guarantee. If within the first 60 days of receipt you are not satisfied with Wake Up Lean™, you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.
Health
The Prostate Massage Manual: What Every Man Needs To Know For Better Prostate Health and Sexual Pleasure
Product Name: The Prostate Massage Manual: What Every Man Needs To Know For Better Prostate Health and Sexual Pleasure
All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.
The Prostate Massage Manual: What Every Man Needs To Know For Better Prostate Health and Sexual Pleasure is backed with a 60 Day No Questions Asked Money Back Guarantee. If within the first 60 days of receipt you are not satisfied with Wake Up Lean™, you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.
Health
Subliminal affirmations videos – Abundantmind
![](https://canadanewsmedia.ca/wp-content/uploads/2024/09/Subliminal-affirmations-videos-–-Abundantmind.jpg)
Product Name: Subliminal affirmations videos – Abundantmind
All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.
Subliminal affirmations videos – Abundantmind is backed with a 60 Day No Questions Asked Money Back Guarantee. If within the first 60 days of receipt you are not satisfied with Wake Up Lean™, you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.
-
News17 hours ago
Canada surpasses gold, total medal count from Tokyo Paralympics on Day 9
-
Health12 hours ago
Heal Your Dog Naturally
-
News17 hours ago
Canadian resident arrested in Quebec over alleged New York terror plot
-
News23 hours ago
Clinton Orr & Jodi Ruta are Committed to Strengthening the Beausejour, Manitoba Community
-
Sports19 hours ago
Whitecaps look for others to seize opportunity in home matchup versus FC Dallas
-
News19 hours ago
Fatal shooting of man who stabbed mother and child justified: Alberta police watchdog
-
Sports18 hours ago
Canadian wheelchair racer Cody Fournie golden again in Paralympic Games
-
News12 hours ago
Canada women beaten by Brazil, drop to third place in Group B at FIFA U-20 World Cup